`Wisconsin Attorney General
`
` P.O. Box 7857
` Madison, WI 53707-7857
`
`NEWS FOR IMMEDIATE RELEASE
`
`December 13, 2017
`
`AG Schimel and UW System Team Up with Adapt Pharma to Expand
`Narcan Availability on University Campuses
`UW System Has First System-wide NARCAN Initiative in Nation
`
`MADISON, Wis. – Attorney General Brad Schimel and University of Wisconsin
`System President Ray Cross are expanding access and affordability of the live-saving
`opiate antidote, NARCAN® Nasal Spray, through a partnership with the drug’s
`manufacturer, Adapt Pharma, Inc. that was announced today.
`
`"Earlier this year, DOJ partnered with Adapt Pharma to expand NARCAN® access
`in Wisconsin and once again we are partnering to extend NARCAN®'s reach,"
`said Attorney General Schimel. "University of Wisconsin System President Cross is
`committed to the health and well-being of Wisconsin college students, and this new
`partnership will allow college campuses to have this potentially life-saving
`medication at the ready."
`
`Law enforcement and campus security across nine campuses will be provided
`NARCAN® Nasal Spray 4mg at no cost, including: UW-Eau Claire, UW-Green Bay,
`UW-La Crosse, UW-Oshkosh, UW-Platteville, UW-River Falls, UW-Stevens Point,
`UW-Stout, and UW-Superior. UW-Madison, UW-Milwaukee, UW-Parkside and UW-
`Whitewater have other partnerships in place for NARCAN® doses ensuring that all
`UW campuses have the antidote available.
`
`"This will be a critical resource for our campus communities, and we are very
`appreciative of the partnership with the Department of Justice to receive NARCAN®
`from Adapt Pharma. The UW System has been actively working with recovery
`stakeholders in Wisconsin to demonstrate our shared commitment in the fight
`against opioid use, and this is an important tool for our officers," said University of
`Wisconsin System President Ray Cross.
`
`Opiant Exhibit 2141
`Nalox-1 Pharmaceuticals, LLC v. Opiant Pharmaceuticals, Inc.
`IPR2019-00688
`Page 1
`
`
`
`
`NARCAN® Nasal Spray is an FDA-approved naloxone in a nasal spray for the
`emergency treatment of prescription opioid, fentanyl and heroin-related overdose.
`NARCAN® Nasal Spray is a ready-to-use, needle-free, 4mg dose of naloxone in a
`single spray. Its design makes it easy for both medical and non-medical personnel to
`administer a concentrated naloxone dose to restore breathing quickly to those who
`are experiencing an opioid overdose. The use of naloxone in Wisconsin has been
`widespread in recent years thanks to the work of Rep. John Nygren and his Heroin,
`Opioid Prevention and Education (H.O.P.E.) legislation, which has expanded law
`enforcement training and access to the life-saving drug.
`
`"The NARCAN® Nasal Spray for Schools program demonstrates the important role
`academic institutions have in educating students about opioid misuse and the risk of
`opioid pain medications," said Mike Kelly, President of U.S. Operations at Adapt
`Pharma. “We applaud the University of Wisconsin System's leadership in preparing
`its campuses for an opioid overdose emergency."
`
`
`Opiant Exhibit 2141
`Nalox-1 Pharmaceuticals, LLC v. Opiant Pharmaceuticals, Inc.
`IPR2019-00688
`Page 2
`
`
Accessing this document will incur an additional charge of $.
After purchase, you can access this document again without charge.
Accept $ Charge
Still Working On It
This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.
Give it another minute or two to complete, and then try the refresh button.
A few More Minutes ... Still Working
It can take up to 5 minutes for us to download a document if the court servers are running slowly.
Thank you for your continued patience.
This document could not be displayed.
We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.
Your account does not support viewing this document.
You need a Paid Account to view this document. Click here to change your account type.
Your account does not support viewing this document.
Set your membership
status to view this document.
With a Docket Alarm membership, you'll
get a whole lot more, including:
- Up-to-date information for this case.
- Email alerts whenever there is an update.
- Full text search for other cases.
- Get email alerts whenever a new case matches your search.
One Moment Please
The filing “” is large (MB) and is being downloaded.
Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.
Your document is on its way!
If you do not receive the document in five minutes, contact support at support@docketalarm.com.
Sealed Document
We are unable to display this document, it may be under a court ordered seal.
If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.
Access Government Site
